To test this hypothesis, we treated ALK-driven NB cells with increasing concentrations of the ALK inhibitor lorlatinib, the IGF1R inhibitor GSK1904529A, or a combination of both for three days. This evidence concerns the gene IGF1R and neuroblastoma.